Uterine metastases in ovarian carcinoma: Frequency and survival in women who underwent hysterectomy

Journal of Gynecologic Oncology

Volumn 21, Issue 3, 2010, Pages 191-195

  Menczer, Joseph ^a,b   Chetrit, Angela ^c   Sadetzki, Siegal ^b,c  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

Epithelial ovarian carcinoma; Survival; Uterine involvement

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL OVARY CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; ISRAEL; JEW; MAJOR CLINICAL STUDY; METASTASIS; MICROSCOPY; OVARY CARCINOMA; OVERALL SURVIVAL; UTERUS METASTASIS;

EID: 78049486964     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.3.191     Document Type: Article

References (27)

1. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 2000; 19: 11-9.
2. Trope C, Kaern J. Primary surgery for ovarian cancer. Eur J Surg Oncol 2006; 32: 844-52.
3. Leitao MM Jr, Chi DS. Operative management of primary epi-thelial ovarian cancer. Curr Oncol Rep 2007; 9: 478-84.
4. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007; 25: 2873-83.
5. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovar-ian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-40.
6. Julian CG, Goss J, Blanchard K, Woodruff JD. Biologic behavior of primary ovarian malignancy. Obstet Gynecol 1974; 44: 873-84.
7. Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer: an autopsy study. Cancer 1989; 64: 1508-13.
8. Reed E, Zerbe CS, Brawley OW, Bicher A, Steinberg SM. Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988. Am J Clin Oncol 2000; 23: 107-16.
9. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106: 1624-33.
10. Guth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G. Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer 2007; 110: 1272-80.
11. Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Stoler MH, Beecham JB, et al. Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 1988; 19: 57-63.
12. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2003; 83 Suppl 1: 135-66.
13. McComas BC, Farnum JB, Donaldson RC. Ovarian carcinoma presenting as a cervical metastasis. Obstet Gynecol 1984; 63: 593-6.
14. Mazur MT, Hsueh S, Gersell DJ. Metastases to the female geni-tal tract: analysis of 325 cases. Cancer 1984; 53: 1978-84.
15. Lemoine NR, Hall PA. Epithelial tumors metastatic to the ute-rine cervix: a study of 33 cases and review of the literature. Cancer 1986; 57: 2002-5.
16. Lyon DS, Kaminski PF, Wheelock JB. Significance of a positive Papanicolaou smear in a well screened population. South Med J 1989; 82: 190-2.
17. Guidozzi F, Sonnendecker EW, Wright C. Ovarian cancer with metastatic deposits in the cervix, vagina, or vulva preceding primary cytoreductive surgery. Gynecol Oncol 1993; 49: 225-8.
18. Tarraza HM, Muntz HG, De Cain M, Jones MA. Cervical meta-stases in advanced ovarian malignancies. Eur J Gynaecol Oncol 1993; 14: 274-8.
19. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcino-mas: a prospective clinicopathologic study of 74 cases: a gyne-cologic oncology group study. Gynecol Oncol 2001; 83: 355-62.
20. Williams MG, Bandera EV, Demissie K, Rodriguez-Rodriguez L. Synchronous primary ovarian and endometrial cancers: a pop-ulation-based assessment of survival. Obstet Gynecol 2009; 113: 783-9.
21. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-59.
22. Memarzadeh S, Berek JS. Advances in the management of epi-thelial ovarian cancer. J Reprod Med 2001; 46: 621-9.
23. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before sur-gery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003; 90: 390-6.
24. Heintz AP. Surgery in advanced ovarian carcinoma: is there proof to show the benefit? Eur J Surg Oncol 1988; 14: 91-9.
25. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000; 78: 269-74.
26. Menczer J. Cytoreductive surgery in the treatment of advanced ovarian carcinoma: some controversial aspects. Eur J Gynaecol Oncol 1992; 13: 246-55.
27. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of sur-gery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-11.